Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Third-Quarter 2014 Financial Results


      News provided by

      AbbVie

      31 Oct, 2014, 12:59 GMT

      Share this article

      Share this article


      - Reports Third-Quarter Adjusted EPS of $0.89, Up 8.5 Percent and Well Above the Previous Guidance Range of $0.77 to $0.79; Reports GAAP EPS of $0.31

      - Significantly Raises 2014 Adjusted EPS Guidance Range to $3.25 to $3.27 from $3.06 to $3.16 (GAAP EPS Guidance Range is $1.15 to $1.17); 2014 Guidance Excludes Any Potential HCV Revenue

      - Delivers Revenue of $5.019 Billion, an Increase of 7.8 Percent Over Third-Quarter 2013 (Up 8.3 Percent On an Operational Basis); Revenue Up 13.5 Percent Operationally Excluding Lipid Sales

      - Revenue Growth Reflects 17.5 Percent Global Sales Growth from HUMIRA (Up 17.8 Percent on an Operational Basis) and Strong Growth from Other Key Products

      - Continues to Expect U.S. Approval of HCV Combination in 2014; Announced Novel R&D Collaboration with Calico to Develop Medicines for Age-Related Diseases; Further Strengthened Pipeline with Global Collaboration to Develop and Commercialize Duvelisib, PI3K-Inhibitor for Treatment of Cancer

      NORTH CHICAGO, Illinois, Oct. 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014.

      "Our third-quarter results reflect the strong performance of our business with double-digit growth from HUMIRA and several other key brands.  Our underlying business grew nearly 14 percent in the quarter excluding lipids," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.  "We exceeded our outlook for the quarter and have significantly raised our original 2014 guidance.  In the fourth quarter, we look forward to the U.S. approval of our interferon-free HCV combination, which will further accelerate sales and earnings growth in 2015 and beyond."

      Third-Quarter Results

      • Worldwide sales were $5.019 billion in the third quarter, up 7.8 percent. On an operational basis, sales increased 8.3 percent, excluding a 0.5 percent unfavorable impact from foreign exchange rate fluctuations. Excluding sales from our lipid franchise due to the loss of exclusivity, sales increased 13.5 percent on an operational basis in the quarter.
      • Third-quarter sales growth was driven primarily by the continued strength of HUMIRA. Global HUMIRA sales increased 17.5 percent, or 17.8 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations. Total company sales growth was also driven by strong growth from key products including Kaletra, Synthroid, Creon, Synagis and Duodopa.
      • The adjusted gross margin ratio in the third quarter was 81.1 percent, excluding intangible asset amortization and other specified items, up 140 basis points versus third-quarter 2013. The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 78.2 percent.
      • Adjusted selling, general and administrative (SG&A) expense was 26.4 percent of sales in the third quarter, up 9.1 percent from the prior year, reflecting continued investment in our growth brands and the expected HCV launch. On a GAAP basis, SG&A was 31.8 percent of sales.
      • Adjusted research and development (R&D) was 16.2 percent of sales in the quarter, up 14.4 percent from the prior year, reflecting funding actions in support of our mid- and late-stage pipeline and the continued pursuit of additional HUMIRA indications. On a GAAP basis, R&D was also 16.2 percent of sales. 
      • Net interest expense was $53 million on an adjusted basis and $128 million on a GAAP basis. The adjusted tax rate was 22.4 percent in the quarter and 26.3 percent on a GAAP basis.
      • Third-quarter diluted earnings per share were $0.31 on a GAAP basis. Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $0.89.

      Key Events from the Third Quarter

      • On Oct. 20, AbbVie and Shire agreed to terminate their proposed merger following the decision by AbbVie's board of directors on Oct. 15 to withdraw support for the proposed transaction. The Company's decision was based upon its assessment of the Sept. 22, 2014 notice issued by the U.S. Department of Treasury. This notice included changes that negatively impacted the economics of the transaction. As a result, the original price for the proposed transaction could no longer be justified. The notice also introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes and the stated intention of the Department of Treasury to continue to revise tax principles to further impact such transactions.
      • On Oct. 20, the AbbVie board of directors authorized a new $5 billion stock repurchase program and increased the company's quarterly cash dividend by nearly 17 percent from $0.42 per share to $0.49 per share, payable on Feb. 13, 2015 to stockholders of record as of Jan. 15, 2015. Additionally, on Sept. 19, the board of directors declared a quarterly cash dividend of $0.42 per share, payable Nov. 17, 2014 to stockholders of record at the close of business on Oct. 15, 2014.
      • AbbVie and Infinity Pharmaceuticals entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMO, a Phase 2 study in patients with iNHL, and DUO, a Phase 3 study in patients with CLL.
      • AbbVie and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer. Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies: Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development; and AbbVie will provide scientific and clinical development expertise and its strong commercial execution to bring new discoveries to market.
      • The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. Glioblastoma multiforme is the most common and most aggressive type of malignant primary brain tumor and has a five year survival rate of approximately 4 percent.
      • AbbVie announced results from a Phase 3 pivotal study demonstrating that HUMIRA is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. These data were presented at the European Society for Dermatological Research (ESDR) meeting. Results from the PIONEER I study show that HS patients treated with HUMIRA 40 mg weekly achieved a significantly greater response versus those on placebo at week 12. AbbVie also recently presented new results from PIONEER II, a second pivotal HS study, at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting. The results of this study, in combination with results from PIONEER I, will contribute to worldwide regulatory filings for an expanded use of HUMIRA.
      • AbbVie and Biogen Idec announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX (interferon beta-1a). These results were presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston. We are engaged with worldwide authorities regarding the regulatory filings for ZINBRYTA. We continue to expect the submissions to occur in the first half of 2015.
      • The FDA approved HUMIRA for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home. Additionally, the FDA approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients ages 2 and older.
      • AbbVie announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11. Abstracts will be presented highlighting results from AbbVie's investigational treatment combining three direct-acting antivirals (ABT-450/ritonavir, ombitasvir and dasabuvir) with or without ribavirin (RBV) in patients with genotype 1 chronic HCV infection. These abstracts include a Phase 2/3 study in patients co-infected with human immunodeficiency virus type 1 (TURQUOISE-I) and a Phase 2 study in liver transplant recipients without cirrhosis (CORAL-I). Additionally, Phase 2 data will be presented from investigational studies evaluating the combination of ABT-450/ritonavir and ombitasvir with or without RBV in genotype 4 patients (PEARL-I). AbbVie will also be presenting data from its two additional pipeline HCV compounds, ABT-493 and ABT-530.
      • AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement in progression-free survival and a 30 percent improvement in overall survival in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).  These results, which evaluated veliparib as a potential treatment for metastatic or advanced NSCLC, were presented for the first time at the 2014 Annual Congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain.

      Full-Year 2014 Outlook

      Today, AbbVie is raising its adjusted diluted earnings-per-share guidance for the full-year 2014 to $3.25 to $3.27 from $3.06 to $3.16. AbbVie's 2014 outlook continues to exclude any potential revenue from the expected 2014 U.S. launch of its HCV therapy.  The company's 2014 adjusted diluted earnings-per-share guidance excludes $2.10 per share of intangible asset amortization expense and other specified items primarily associated with separation costs, acquired IPR&D, Shire transaction costs and the Branded Prescription Drug Fee.  Including these items, AbbVie's diluted earnings-per-share guidance is $1.15 to $1.17 on a GAAP basis. 

      About AbbVie

      AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.  The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.  AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.  For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.  Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our third-quarter performance.  Participating on the call will be Rick Gonzalez, chairman and chief executive officer; Bill Chase, executive vice president and chief financial officer; Laura Schumacher, executive vice president, business development, external affairs and general counsel; Mike Severino, executive vice president, research and development and chief scientific officer; and Larry Peepo, vice president, investor relations.  The call will be webcast through AbbVie's Web site at www.abbvieinvestor.com.   

      Non-GAAP Financial Results

      Financial results for 2013 and 2014 are presented on both a reported and a non-GAAP basis.  Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period.  Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release.  AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business.  Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.  The company's 2014 financial guidance is also being provided on both a reported and a non-GAAP basis. 

      Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.  Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K and in Item 1A, "Risk Factors" of Part II of AbbVie's second quarter 2014 Quarterly Report on Form 10-Q, which have been filed with the Securities and Exchange Commission.  AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

      AbbVie Inc.

      Key Product Sales

      Quarter Ended Sept. 30, 2014

      (Unaudited)




      % Change vs. 3Q13


      Sales (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      TOTAL SALES

      $2,809

      $2,210

      $5,019

      7.4%

      9.5%

      8.2%

      8.3%

      7.8%

      Humira

      1,739

      1,516

      3,255

      25.3

      10.3

      9.7

      17.8

      17.5

      Kaletra

      53

      203

      256

      (14.1)

      19.7

      16.5

      10.7

      8.4

      AndroGel

      232

      --

      232

      (6.7)

      n/a

      n/a

      (6.7)

      (6.7)

      Synthroid

      200

      --

      200

      24.3

      n/a

      n/a

      24.3

      24.3

      Lupron

      147

      49

      196

      3.9

      (8.4)

      (10.0)

      0.4

      --

      Creon

      148

      --

      148

      47.6

      n/a

      n/a

      47.6

      47.6

      Sevoflurane

      20

      114

      134

      0.9

      (1.1)

      (3.3)

      (0.8)

      (2.7)

      Synagis

      --

      109

      109

      n/a

      18.3

      11.9

      18.3

      11.9

      Dyslipidemia

      63

      --

      63

      (76.9)

      n/a

      n/a

      (76.9)

      (76.9)

      Duodopa

      --

      56

      56

      n/a

      20.8

      20.2

      20.8

      20.2


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor.


      n/a = not applicable

      AbbVie Inc.

      Key Product Sales

      Nine Months Ended Sept. 30, 2014

      (Unaudited)




      % Change vs. 9M13


      Sales (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      TOTAL SALES

      $7,681

      $6,827

      $14,508

      4.3%

      9.3%

      8.1%

      6.6%

      6.1%

      Humira

      4,592

      4,588

      9,180

      28.7

      13.4

      13.2

      20.6

      20.5

      AndroGel

      704

      --

      704

      (5.7)

      n/a

      n/a

      (5.7)

      (5.7)

      Kaletra

      163

      504

      667

      (9.9)

      (6.6)

      (8.8)

      (7.4)

      (9.1)

      Lupron

      420

      151

      571

      2.5

      (5.7)

      (8.9)

      0.1

      (0.8)

      Synagis

      --

      537

      537

      n/a

      12.0

      4.7

      12.0

      4.7

      Synthroid

      523

      --

      523

      20.8

      n/a

      n/a

      20.8

      20.8

      Sevoflurane

      61

      369

      430

      12.1

      5.7

      3.2

      6.6

      4.4

      Creon

      365

      --

      365

      23.2

      n/a

      n/a

      23.2

      23.2

      Dyslipidemia

      224

      --

      224

      (77.3)

      n/a

      n/a

      (77.3)

      (77.3)

      Duodopa

      --

      164

      164

      n/a

      24.5

      26.9

      24.5

      26.9


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor.


      n/a = not applicable

      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Nine Months Ended Sept. 30, 2014 and 2013

      (Unaudited) (In millions, except per share data)



      Third Quarter
      Ended Sept. 30


      Nine Months
      Ended Sept. 30



      2014


      2013


      2014


      2013


      Net sales

      $5,019


      $4,658


      $14,508


      $13,679











      Cost of products sold

      1,094


      1,092


      3,307


      3,299


      Selling, general and administrative

      1,595


      1,261


      4,383


      3,904


      Research and development

      812


      714


      2,418


      2,057


      Acquired in-process research and development

      308


      220


      324


      290


      Total operating cost and expenses

      3,809


      3,287


      10,432


      9,550











      Operating earnings

      1,210


      1,371


      4,076


      4,129











      Interest expense, net

      128


      69


      262


      210


      Net foreign exchange loss

      174


      11


      182


      40


      Other (income) expense, net

      221


      5


      226


      (14)


      Earnings before income tax expense

      687


      1,286


      3,406


      3,893


      Income tax expense

      181


      322


      822


      893


      Net earnings

      $506


      $964


      $2,584


      $3,000











      Diluted earnings per share

      $0.31


      $0.60


      $1.60


      $1.86


      Diluted earnings per share, excluding specified items

      $0.89


      $0.82


      $2.43


      $2.32

      a)










      Average diluted shares outstanding

      1,610


      1,605


      1,609


      1,602



      a) Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.


      Note: The computation of diluted earnings per share for the quarter and nine months ended Sept. 30, 2014 and 2013 were calculated pursuant to the two-class method which requires the allocation of net earnings between common stockholders and participating security holders.


      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended Sept. 30, 2014

      (Unaudited) (In millions, except per share data)



      1. Specified items impacted results as follows:



      3Q14



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $687

      $506

      $0.31


      Adjusted for specified items:





      Intangible asset amortization

      98

      70

      0.04


      Separation costs

      109

      98

      0.06


      Acquired IPR&D

      308

      206

      0.13


      Calico collaboration

      250

      250

      0.15


      Shire transaction costs

      276

      172

      0.11


      Other

      139

      147

      0.09


      As adjusted (non-GAAP)

      $1,867

      $1,449

      $0.89




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D primarily reflects the upfront payment related to the Infinity collaboration. Calico collaboration reflects the upfront payment related to the recently announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Other specified items are primarily associated with an additional year of the Branded Prescription Drug Fee as required by new IRS regulations.



      2. The impact of the specified items by line item was as follows:





      3Q14



      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Net foreign exchange loss

      Interest expense (income)

      Other (income) expense


      As reported (GAAP)

      $1,094

      $1,595

      $812

      $308

      $174

      $128

      $221


      Adjusted for specified items:









      Intangible asset amortization

      (98)

      --

      --

      --

      --

      --

      --


      Separation costs

      (4)

      (104)

      (1)

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      (308)

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      --

      (250)


      Shire transaction costs

      --

      (36)

      --

      --

      (165)

      (75)

      --


      Other

      (44)

      (129)

      --

      --

      --

      --

      34


      As adjusted (non-GAAP)

      $948

      $1,326

      $811

      --

      $9

      $53

      $5



      3. The adjusted tax rate for the third quarter of 2014 was 22.4 percent, as detailed below:





      3Q14



      Pre-tax

      Income




      income

      Taxes

      Tax rate


      As reported (GAAP)

      $687

      $181

      26.3%


      Specified items

      1,180

      237

      20.1%


      As adjusted (non-GAAP)

      $1,867

      $418

      22.4%


      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Quarter Ended Sept. 30, 2013


      (Unaudited) (In millions, except per share data)



      1. Specified items impacted results as follows:



      3Q13



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $1,286

      $964

      $0.60


      Adjusted for specified items:





      Intangible asset amortization

      137

      98

      0.06


      Separation costs

      51

      33

      0.02


      Acquired IPR&D

      220

      220

      0.13


      Restructuring/Other

      14

      12

      0.01


      As adjusted (non-GAAP)

      $1,708

      $1,327

      $0.82




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects the upfront payment related to the previously announced collaborations with Ablynx and Galapagos. Restructuring/Other is primarily associated with previously announced restructuring activities.


      2. The impact of the specified items by line item was as follows:






      3Q13



      Cost of
      products
      sold

      SG&A

      R&D

      Acquired
      IPR&D

      Other
      (income)
      expense


      As reported (GAAP)

      $1,092

      $1,261

      $714

      $220

      $5


      Adjusted for specified items:







      Intangible asset amortization

      (137)

      --

      --

      --

      --


      Separation costs

      (4)

      (46)

      (1)

      --

      --


      Acquired IPR&D

      --

      --

      --

      (220)

      --


      Restructuring/Other

      (7)

      --

      (4)

      --

      (3)


      As adjusted (non-GAAP)

      $944

      $1,215

      $709

      --

      $2


      3. The adjusted tax rate for the third quarter was 22.3 percent, as detailed below:




      3Q13



      Pre-tax

      Income




      income

      taxes

      Tax rate


      As reported (GAAP)

      $1,286

      $322

      25.0%


      Specified items

      422

      59

      14.0%


      As adjusted (non-GAAP)

      $1,708

      $381

      22.3%


      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Nine Months Ended Sept. 30, 2014


      (Unaudited) (In millions, except per share data)



      1. Specified items impacted results as follows:





      9M14



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $3,406

      $2,584

      $1.60


      Adjusted for specified items:





      Intangible asset amortization

      307

      218

      0.14


      Separation costs

      299

      282

      0.17


      R&D

      40

      40

      0.03


      Acquired IPR&D

      324

      222

      0.14


      Calico collaboration

      250

      250

      0.15


      Shire transaction costs

      283

      179

      0.11


      Other

      148

      154

      0.09


      As adjusted (non-GAAP)

      $5,057

      $3,929

      $2.43




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. R&D is associated with payments for previously announced collaborations. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Calico collaboration reflects the upfront payment related to the recently announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Other is associated with restructuring activities and an additional year of the Branded Prescription Drug Fee as required by new IRS regulations.


      2. The impact of the specified items by line item was as follows:





      9M14



      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Net foreign exchange loss

      Interest expense (income)

      Other (income) expense


      As reported (GAAP)

      $3,307

      $4,383

      $2,418

      $324

      $182

      $262

      $226


      Adjusted for specified items:









      Intangible asset amortization

      (307)

      --

      --

      --

      --

      --

      --


      Separation costs

      (10)

      (286)

      (3)

      --

      --

      --

      --


      R&D

      --

      --

      (40)

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      (324)

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      --

      (250)


      Shire transaction costs

      --

      (43)

      --

      --

      (165)

      (75)

      --


      Other

      (51)

      (131)

      --

      --

      --

      --

      34


      As adjusted (non-GAAP)

      $2,939

      $3,923

      $2,375

      --

      $17

      $187

      $10


      3. The adjusted tax rate for the first nine months of 2014 was 22.3 percent, as detailed below:




      9M14



      Pre-tax

      Income




      income

      Taxes

      Tax rate


      As reported (GAAP)

      $3,406

      $822

      24.1%


      Specified items

      1,651

      306

      18.5%


      As adjusted (non-GAAP)

      $5,057

      $1,128

      22.3%


      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Nine Months Ended Sept. 30, 2013


      (Unaudited) (In millions, except per share data)



      1. Specified items impacted results as follows:





      9M13



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $3,893

      $3,000

      $1.86


      Adjusted for specified items:





      Intangible asset amortization

      408

      294

      0.18


      Separation costs

      152

      97

      0.06


      Acquired IPR&D

      290

      290

      0.18


      Restructuring/Other

      70

      60

      0.04


      As adjusted (non-GAAP)

      $4,813

      $3,741

      $2.32




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects the upfront payment related to previously announced collaborations. Restructuring/Other is primarily associated with previously announced restructuring activities and the impact of the Venezuelan currency devaluation.



      2. The impact of the specified items by line item was as follows:





      9M13



      Cost of
      products
      sold

      SG&A

      R&D

      Acquired IPR&D

      Net foreign
      exchange
      loss

      Other
      (income)
      expense


      As reported (GAAP)

      $3,299

      $3,904

      $2,057

      $290

      $40

      ($14)


      Adjusted for specified items:








      Intangible asset amortization

      (408)

      --

      --

      --

      --

      --


      Separation costs

      (11)

      (135)

      (6)

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      (290)

      --

      --


      Restructuring/Other

      3

      (38)

      (15)

      --

      (11)

      (9)


      As adjusted (non-GAAP)

      $2,883

      $3,731

      $2,036

      --

      $29

      ($23)


      3. The adjusted tax rate for the first nine months of 2013 was 22.3 percent, as detailed below:




      9M13



      Pre-tax

      Income




      income

      taxes

      Tax rate


      As reported (GAAP)

      $3,893

      $893

      22.9%


      Specified items

      920

      179

      19.5%


      As adjusted (non-GAAP)

      $4,813

      $1,072

      22.3%

      Modal title

      Also from this source

      AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

      AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with ...

      AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

      AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.